Results 31 to 40 of about 2,738 (166)

Homozygous familial hypercholesterolemia with stenosis of the left anterior descending coronary artery successfully treated with weekly low‐density lipoprotein apheresis for 16 years without percutaneous coronary intervention

Clinical Case Reports, 2019
We successfully treated a patient with homozygous familial hypercholesterolemia (HoFH) with stable coronary arterial disease using optimal medical therapy and low‐density lipoprotein (LDL) apheresis for 16 years without percutaneous coronary intervention
Takanori Yasu, Masahiro Shimoyama, Hiroshi Wada, Tomohiro Iwakura, Shigeru Toyoda, Atsuhiko Kawabe, Takushi Sugiyama   +6 more
doaj   +1 more source

Lipoprotein-apheresis reduces circulating microparticles in individuals with familial hypercholesterolemia[S]

Journal of Lipid Research, 2014
Lipoprotein-apheresis (apheresis) removes LDL-cholesterol in patients with severe dyslipidemia. However, reduction is transient, indicating that the long-term cardiovascular benefits of apheresis may not solely be due to LDL removal. Microparticles (MPs)
Katherine D. Connolly, Gareth R. Willis, Dev B.N. Datta, Elizabeth A. Ellins, Kristin Ladell, David A. Price, Irina A. Guschina, D. Aled Rees, Philip E. James   +8 more
doaj   +1 more source

Effectiveness of a Novel Low‐Density Lipoprotein Apheresis Device Rheocarna in Patients Undergoing Hemodialysis With Chronic Limb‐Threatening Ischemia: A Single‐Center Retrospective Study

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Chronic limb‐threatening ischemia (CLTI) is a severe form of lower‐extremity artery disease characterized by distal lesions and microcirculatory impairment, limiting revascularization efficacy. Rheocarna is a direct hemoperfusion low‐density lipoprotein (LDL) adsorption device with potential rheological and anti‐inflammatory ...
Kunihiro Ishioka, Takayasu Ohtake, Kei Ohmori, Chika Shibuya, Tomoki Tsukahara, Mizuki Yamano, Yasuhiro Mochida, Machiko Oka, Kyoko Maesato, Yusuke Tsukamoto, Hidekazu Moriya, Sumi Hidaka, Shuzo Kobayashi   +12 more
wiley   +1 more source

Preoperative Low-Density Lipoprotein Apheresis for Preventing Recurrence of Focal Segmental Glomerulosclerosis after Kidney Transplantation

Journal of Transplantation, 2018
Background. Focal segmental glomerulosclerosis (FSGS) often develops rapidly and frequently progresses to renal failure, while the recurrence rate after kidney transplantation is 20–50%.
Akihito Sannomiya, Toru Murakami, Ichiro Koyama, Kosaku Nitta, Ichiro Nakajima, Shohei Fuchinoue   +5 more
doaj   +1 more source

Barriers to the Implementation of Lipoprotein Apheresis in Canada

Canadian Journal of Cardiology, 2017
This article details the effectiveness of using lipoprotein apheresis (LA) rather than plasmapheresis in patients with homozygous familial hypercholesterolemia (HoFH), using results from the first HoFH pediatric patient treated with LA in Ontario. We further detail the barriers involved in adhering to international guidelines by implementing this as a ...
Guido Filler, Misan Lee, Robert A. Hegele   +2 more
openaire   +4 more sources

Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia1

Journal of Lipid Research, 2012
We measured oxidized phospholipids (OxPL), lipoprotein (a) [Lp(a)], and lipoprotein-associated phospholipase A2 (Lp-PLA2) pre- and postapheresis in 18 patients with familial hypercholesterolemia (FH) and with low(∼10 mg/dl; range 10–11 mg/dl ...
Kiyohito Arai, Alexina Orsoni, Ziad Mallat, Alain Tedgui, Joseph L. Witztum, Eric Bruckert, Alexandros D. Tselepis, M. John Chapman, Sotirios Tsimikas   +8 more
doaj   +1 more source

Pregnancy in a Woman with Homozygous Familial Hypercholesterolemia Not on Low-Density Lipoprotein Apheresis

American Journal of Perinatology Reports, 2012
Pregnancy in women with homozygous familial hypercholesterolemia (FH) has been rarely reported and might pose risks on the mother and her fetus. Although most reported cases remained on low-density lipoprotein (LDL) apheresis, there are no clear ...
Akl C. Fahed, Anwar H. Nassar
doaj   +1 more source

Chimeric Antigen Receptor T‐Cells in Myasthenia Gravis: Advances, Safety Challenges, and Future Directions

Muscle &Nerve, Volume 73, Issue 6, Page 942-951, June 2026.
ABSTRACT This review examines the emerging application of chimeric antigen receptor (CAR) T‐cell therapy in myasthenia gravis (MG), with emphasis on safety, efficacy signals, and future therapeutic potential in treatment‐refractory disease. A comprehensive literature search was conducted across PubMed, medRxiv, bioRxiv, and Google Scholar for studies ...
Tobias Hegelmaier, Alexander Duscha, Christiane Desel, Sarah Stassen, Tim Krzemien, Ann‐Katrin Hennemann, Vaia Pappa, Aiden Haghikia   +7 more
wiley   +1 more source

Impact of LDL apheresis on atheroprotective reverse cholesterol transport pathway in familial hypercholesterolemia

Journal of Lipid Research, 2012
In familial hypercholesterolemia (FH), low HDL cholesterol (HDL-C) levels are associated with functional alterations of HDL particles that reduce their capacity to mediate the reverse cholesterol transport (RCT) pathway.
Alexina Orsoni, Elise F. Villard, Eric Bruckert, Paul Robillard, Alain Carrie, Dominique Bonnefont-Rousselot, M. John Chapman, Geesje M. Dallinga-Thie, Wilfried Le Goff, Maryse Guerin   +9 more
doaj   +1 more source

Systematic Review of Low‐Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
BackgroundApheresis is an important treatment for reducing low‐density lipoprotein cholesterol (LDL‐C) in patients with familial hypercholesterolemia (FH). We systematically reviewed the current literature surrounding LDL‐C apheresis for FH.
Anthony Wang, Akshara Richhariya, Shravanthi R. Gandra, Brian Calimlim, Lisa Kim, Ruben G. W. Quek, Robert J. Nordyke, Peter P. Toth   +7 more
doaj   +1 more source